Previous close | 0.7050 |
Open | 0.7000 |
Bid | 0.6950 x 334700 |
Ask | 0.7100 x 1317400 |
Day's range | 0.6950 - 0.7150 |
52-week range | 0.6200 - 1.4950 |
Volume | |
Avg. volume | 362,176 |
Market cap | 283.868M |
Beta (5Y monthly) | 1.40 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 25 Mar 1988 |
1y target est | N/A |
In a major development for its VIRALEZE™ antiviral nasal spray, Starpharma (ASX: SPL) today announced that its potent antiviral agent, SPL7013, achieved the maximum possible virucidal effect against the highly transmissible Omicron variant of SARS-CoV-2.
Australian biotech company Starpharma has signed a 5-year supply and distribution arrangement for its VIRALEZE™ antiviral nasal spray in Vietnam, with a minimum commitment of 1 million units in the first year.
Australian biotech company Starpharma today announced that its broad spectrum antiviral nasal spray, VIRALEZE™, has been registered for sale in Vietnam, with the product scheduled to launch in Vietnam this week.